OBSVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (23 3月 2023 @ 05:00):

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy...

Stats
本日の出来高	8.23M
平均出来高	7.95M
時価総額	11.00M
EPS	$0 ( 2024-03-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.138
ATR14	$0.0240 (28.57%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-06	Loumaye Ernest	Buy	4 000 000	Common Shares
2023-02-28	Loumaye Ernest	Buy	4 000 000	Common Shares
2023-02-23	Brown William Michael	Buy	250 000	Employee Stock Option (right to buy)
2023-01-01	Loumaye Ernest	Sell	0	Common Stock
2023-01-01	Mathers Edward T	Sell	32 000	Stock Option (right to buy)

INSIDER POWER
77.05
Last 14 transactions
Buy: 8 250 000 \| Sell: 1 374 140

ボリューム相関

長: 0.13 (neutral)

短: 0.22 (neutral)

Signal:(39.484) Neutral

Obseva SA 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Obseva SA 相関 - 通貨/商品

-0.36
( neutral )

-0.70
( moderate negative )

0.00
( neutral )

-0.49
( neutral )

0.24
( neutral )

0.38
( neutral )

Obseva SA 財務諸表

Annual	2022
収益:	$19.64M
総利益:	$19.64M (100.00 %)
EPS:	$-0.320

FY	2022
収益:	$19.64M
総利益:	$19.64M (100.00 %)
EPS:	$-0.320

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.337

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.670

Financial Reports:

No articles found.

Obseva SA

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.